Description
P2.09 Impact of minimal residual disease monitoring on therapy in Belgian childhood acute lymphoblastic leukaemia
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: P2.09 Impact of minimal residual disease monitoring on therapy in Belgian childhood acute lymphoblastic leukaemia
€2.42
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€2.42 Add to cart -
Article: Highlights in gynaecological cancers
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: Calendar of events
€2.42 Add to cart
Reviews
There are no reviews yet.